Dr Kimon Angelides
- Founder and CEO
- FemTec Health, EarlyBird Pharma, Ithaca LifeScience Managing Partner
- United States
Biography:
Kimon Angelides is the founder of six healthcare companies: FemTec Health, Merlin LifeSciences, Vivante Health, EosHealth renamed Livongo (NASDAQ: LVGO) and debuted in July 2019 with a $355M IPO at a $4.4B valuation and recently by Teladoc for $18.5B, DiabetesAmerica, a network of diabetes centers that pioneered bundled payment, provider risk models, and the first remote monitoring of patients, and mAbGen, a cancer biotech company that partnered with world-renowned MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals.
Kimon recently received the 2020 Founder of the Year Award from Rock Health, Goldman Sachs, and PacWest Bank for his contributions and work in digital medicine. Kimon’s newest company, FemTec Health was created in 2020 to bring together all the product and services to create a total healthcare experience for woman and to tackle some of the most complex health conditions using state of the art technologies. The company has taken a multidisciplinary approach using digital therapeutics, diagnostics and discovery medicine, devices, and analytics, all taken to enhance and celebrate women’s health and to break some of the taboos associated with women’s sexual wellness. Vivante Health, that Kimon founded in 2016 after Livongo was formed to meet the needs of people who have invisible and stigmatized diseases, starting with digestive health using new advances and innovations in digital health, telemedicine, and biometric devices.
Prior to his healthcare career, Kimon led strategy for Tanox, Inc., a biotech company now part of Genentech, Director of Strategic Development at St Luke’s/Texas Heart Institute, Professor and Chair of Cell Biology and Biomedical Sciences at the University of Durham in the UK building the pre-clinical services for a new medical school, Professor of Cell Biology, Neuroscience, Biochemistry, and Molecular Biophysics at Baylor College of Medicine, and Associate and Assistant Professor at the University of Florida and McGill University. Kimon was on the National Medical Board of the National Multiple Sclerosis Society, Muscular Dystrophy Association, and the National Institutes of Health. Kimon was a Research Career Development Awardee of the National Institutes of Health, a Mombusho Scholar of Japan, Distinguished Professor at INSERM/Centre National de Recherche Scientifique of France, and a Basil O’Connor Scholar from the March of Dimes Birth Defect Foundation. He has published over 100 papers and holds more than 60 patents. He has a PhD in Bio-organic Chemistry from the University of California and has graduate work in business, laws, and public health.